
20. Giles FJ, le Coutre P and Bhalla K et al. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast (BC) who also failed dasatinib J Clin Onocol 2007 ASCO Annual Meeting Proceedings Part I (25) supp 19S (20 June suppl):7038


32. Larson RA, Chia YL and Granvil C et al. Steady-state imatinib trough levels as well as dose interruptions are associated with clinical response (CCyR and MMR) and adverse events (AEs) in patients with chronic myeloid leukaemia (CML) receiving IM as frontline therapy. Blood (ASH Annual meeting abstracts) 2009;114:2213


36. NICE Guidance on the use of imatinib for chronic myeloid leukaemia. Technology Appraisal 70, October 2003


